The Investor
11 Sep 2026, 18:13
Eli Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Drug Pipeline
Eli Lilly has completed its acquisition of AtaiBeckley, strengthening the pharmaceutical company’s neuroscience pipeline with experimental therapies targeting treatment-resistant depression and other mental health conditions.
AtaiBeckley is a clinical-stage biotechnology company developing rapid-acting neuroplastogens. Its lead investigational program, BPL-003, is being developed for treatment-resistant depression, a condition in which patients continue to experience symptoms despite multiple treatment attempts.
The acquisition gives Lilly access to a pipeline designed around rapid-acting therapies that could potentially reduce reliance on chronic dosing. Lilly said it plans to advance AtaiBeckley’s programs as part of its broader neuroscience strategy.
The transaction was completed after receiving approval from AtaiBeckley shareholders at a special meeting. Financial terms were not disclosed in the announcement.
The deal further expands Lilly beyond its major diabetes and obesity franchises as the company invests across neuroscience, oncology and immunology, with AtaiBeckley adding a new approach to its mental health drug development portfolio.
Eli Lilly has completed its acquisition of AtaiBeckley, strengthening the pharmaceutical company’s neuroscience pipeline with experimental therapies targeting treatment-resistant depression and other mental health conditions.
AtaiBeckley is a clinical-stage biotechnology company developing rapid-acting neuroplastogens. Its lead investigational program, BPL-003, is being developed for treatment-resistant depression, a condition in which patients continue to experience symptoms despite multiple treatment attempts.
The acquisition gives Lilly access to a pipeline designed around rapid-acting therapies that could potentially reduce reliance on chronic dosing. Lilly said it plans to advance AtaiBeckley’s programs as part of its broader neuroscience strategy.
The transaction was completed after receiving approval from AtaiBeckley shareholders at a special meeting. Financial terms were not disclosed in the announcement.
The deal further expands Lilly beyond its major diabetes and obesity franchises as the company invests across neuroscience, oncology and immunology, with AtaiBeckley adding a new approach to its mental health drug development portfolio.
